COAG
Hemab Therapeutics Holdings, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 4 to May 20 ▲ 9 days of insider buys: $53.8M by 1 insider, avg $18.52
- May 26 4 analysts initiate
- Jun 15 to Jun 16 ▲ 2 days of insider buys: $1.7M by 1 insider, avg $24.97
- Aug 11 ▲ Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share)…
- Sep 15 ▼ Short interest jumps 25.3% to 2.64M
- Sep 17 FDA: Hemab Therapeutics Announces First Participant Dosed in Ph…
- Sep 30 ▼ Short interest jumps 28.4% to 3.39M
- Nov 4 FDA: Hemab Therapeutics to Present Clinical and Preclinical Dat…
- Nov 9 ▲ Hemab Therapeutics announced the initiation of SOLARA, a pivotal Pha…
- Nov 9 FDA: Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Tri…
- Nov 9 LifeSci Capital initiates
- Nov 10 ▼ Earnings: COAG Q3 2026 Earnings: EPS $-0.58 (-8.5% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $55.5M. No open-market sales.
- InstitutionsBULLISH
Q3 2026: 14 added (0 new), 3 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.510 → −$0.549 over 90 days. 0 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +4.6% to 3.31M shares. 7.3 days to cover, ≈7.1% of shares.
- TrendUPTREND
6% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | DOUBLED | $43.1M |
| STATE STREET CORP | DOUBLED | $28.6M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $15.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $4.2M |
| UBS Group AG | DOUBLED | $3.3M |
| MORGAN STANLEY | DOUBLED | $929.4K |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | $753.4K |
| MARSHALL WACE, LLP | NEAR_EXIT | $530.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +64%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | LifeSci Capital INITIATE | Outperform |
| Oct 15, 2026 | JP Morgan INITIATE | Overweight |
| Oct 12, 2026 | Rodman & Renshaw INITIATE | Buy |
| Aug 12, 2026 | Wedbush MAINTAIN | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 13, 2026 | Jefferies MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Walbert Keli Director Sep 24, 2026 | AWARD | 36,000 sh |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Jun 16, 2026 | BUY | $1.5M |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner Jun 15, 2026 | BUY | $153.0K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner May 20, 2026 | BUY | $24.8K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner May 19, 2026 | BUY | $94.9K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner May 12, 2026 | BUY | $159.0K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner May 11, 2026 | BUY | $643.0K |
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner May 11, 2026 | BUY | $346.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.55 | -$0.57–-$0.54 | -7.7% | $0.00 |
| Next Q | -$0.61 | -$0.64–-$0.58 | -5.2% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 4 press releases · 1 bullish · 0 bearish · 1 mixed · 13 neutral- NEUTRAL PRESS-RELEASENov 10, 2026
Hemab Therapeutics reported a Q3 2026 net loss of $27.3M ($0.58 per share), wider than the $17.1M…
Monitor enrollment updates for the SOLARA Phase 3 trial and initial Phase 1 data for HMB-003 expected in mid-2027. Data presentations at ASH in December 2026 and EAHAD in February 2027 could provide…
- BULLISH PRESS RELEASENov 9, 2026
Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial of sutacimig…
Monitor enrollment updates and interim data from SOLARA; the single-arm design and FDA's prior recommendation for a randomized trial introduce regulatory risk. Positive Phase 3 results could support…
- NEUTRAL SC 13G/ANov 6, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 4,871,850…
Fidelity's passive 10.4% stake is a routine update. Monitor for any conversion to a 13D (activist filing) or for significant changes in the stake size in future amendments.
- NEUTRAL PRESS RELEASENov 4, 2026
Hemab Therapeutics announced first clinical data for sutacimig in Factor VII deficiency at ASH…
Monitor ASH 2026 presentations (Dec 12-15) for updated sutacimig data including all dosed participants. HMB-003 Phase 1 data in mid-2027 is the next catalyst. No financial impact from this release…
All COAG filing & press-release reports (19)
- PRESS-RELEASE reportNov 10, 2026
- PRESS-RELEASE reportNov 9, 2026
- SC 13G/A reportNov 6, 2026
- PRESS-RELEASE reportNov 4, 2026
- 3 reportSep 25, 2026
- PRESS-RELEASE reportSep 17, 2026
- 8-K reportAug 11, 2026
- INSIDER-BUY reportJun 17, 2026
- PRESS-RELEASE reportMay 21, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- 3 reportApr 30, 2026
- S-1/A reportApr 27, 2026